Project Grant F31CA314322
Award Date 12/1/26
Completion Date 8/31/28
Dollars Obligated $100K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Cancer Institute awarded $413,339 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on chimeric antigen receptor (CAR) T-cell therapy for lymphoma treatment. The research aligns T-cell biology with CAR architecture to enhance lymphoma therapy, addressing the limitation that durable responses are achieved in only 35–50% of lymphoma patients currently...
- The National Cancer Institute awarded Case Western Reserve University $164,190 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, to investigate the role of B-cell activating factor (BAFF) in adverse events associated with chimeric antigen receptor (CAR)-T cell therapy. The research examines BAFF's contribution to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the two most common and potentially life-threatening...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $172,889 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and optimize chimeric antigen receptor (CAR) T-cell therapies for acute myeloid leukemia (AML). The funded research applies structure-guided protein evolution to improve natural ligand-based CAR-T therapies targeting CD70 in AML. The project uses computational deep learning algorithms and high-throughput...
- The National Cancer Institute awarded Emory University $100,228 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026, to support research training in biomedical careers relevant to the National Cancer Program. The award funds investigation of PYCR phosphorylation in chemoimmunotherapy resistance, specifically examining how fibroblast growth factor receptor 1 (FGFR1) phosphorylates proline cycle regulatory enzymes (PYCR1 and PYCR2) and confers resistance to combined...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded Georgia TECH Research Corp $705,899 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop antigen-presenting lipid nanoparticles (APNs) that deliver B cell maturation antigen (BCMA) CAR mRNA to specific immune effector cell subsets for multiple myeloma treatment. The research addresses manufacturing and cost barriers that limit patient access to existing CAR T cell therapies for multiple myeloma. The project will engineer...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $452,540 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the innate and adaptive immune determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T cell therapy. CRS occurs in approximately 93 percent of patients receiving CAR T cell therapy, manifesting as fever, hypotension, hypoxia, and dyspnea due to rapid increases in multiple cytokines...
- The National Cancer Institute awarded The Washington University $548,528 under the Cancer Treatment Research program (CFDA 93.395) on September 3, 2026, to enhance CAR-T cell therapy for relapsed or refractory large B cell lymphoma. The recipient will conduct a Phase 1B clinical trial evaluating early and repeated dosing schedules of NT-I7, a long-acting interleukin-7 therapeutic, administered following axicabtagene ciloleucel or lisocabtagene maraleucel infusion in patients with relapsed or...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $2.554 million on March 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop biomaterial-enhanced CAR-T and CAR natural killer cell therapies for glioblastoma treatment. The award funds a comprehensive research program structured around three interconnected research projects. The first project integrates CAR T cell and CAR natural killer T cell therapy with an acetalated dextran...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...